372 Hollandview Trail, Suite 300
Aurora, ON L4G0A5 Canada
905-727-7989

# PROTOCOL APPROVAL WITH MODIFICATIONS/REB ATTESTATION

| | |
|---|---|
| **DATE:** | 21 May 2021 |
| **TO:** | Chitra Karki, BAMS, MPH |
| **PROTOCOL:** | Takeda Pharmaceuticals, Inc - Pro00053638 / TAK-59, Burden of Illness in Crohn's Disease Patients with and without Perianal Fistulas (CPF and non-PAF): A study in EU4, Canada, Australia, & Japan (Pro00053638) |
| **APPROVAL DATE:** | 20 May 2021 |
| **EXPIRATION DATE:** | 20 May 2022 |

**IRB APPROVED DOCUMENTATION:**

| | |
|---|---|
| **Protocol Version(s):** | • Protocol Version 4.0 (Dated 05 Apr 2021) |
| **Consent Form(s):** | • Informed Consent Form (Advarra IRB Approved Version 20 May 2021) |
| **Other Material:** | • Questionnaire, Observational Burden of Illness study in Perianal Fistula- and non-Perianal Fistula Crohn's Disease Patients (Not Dated) |

The IRB approved the above referenced protocol with the modifications listed below on 20 May 2021:

- **Modifications to the Informed Consent Form**

If you wish to appeal the IRB's determinations and/or imposed modifications, you may follow the procedures outlined below:

1. Submit supporting documentation that addresses the IRB's concerns.
2. Provide a written justification for relief of any IRB imposed condition.

You have been unconditionally approved as the Investigator at your site for the above study.

The IRB granted a Waiver of Documentation of Consent for this study.

Within 30 days prior to study initiation, the Principal Investigator must complete human subject protection training -- at a minimum the completion of the review of GCP Guidelines or TCPS2; or a web-based training program in human subject research protection such as CITI training.

The above referenced subject material is available on your Advarra CIRBI Platform under the "IRB Issued Documents" tab.

If there are any changes to the IRB approved material, IRB approval will be needed prior to use. This includes changes in relative size and type of font in the material to be viewed by potential subjects.

---

If the study is expected to last beyond the approval period, you must request and receive re-approval prior to the expiration date noted above. A report to the Board on the status of this study is due prior to the expiration date or at the time the study closes, whichever is earlier. It is recommended that you submit status reports at least 4 weeks prior to your expiration date to avoid any additional fees or lapses in approval.

Approved investigators and sites are required to submit to Advarra for review, and await a response prior to implementing, any amendments or changes in the protocol; informed consents; advertisements or recruitment materials ("study-related materials"); investigators; or sites (primary and additional).

Approved investigators and sites are required to notify Advarra of the following reportable events, including, but not limited to: unanticipated problems involving risks to subjects or others; unanticipated adverse device effects; protocol violations that may affect the subjects' rights, safety, or well-being and/or the completeness, accuracy and reliability of the study data; subject death; suspension of enrollment; or termination of the study.

**Compliance Statement/Attestation**

The IRB attests that the document(s) have been approved, as described above, and the membership of the IRB complies with the requirements defined in Health Canada regulations, 21 CFR parts 56 and 312.3 and 45 CFR 46. The IRB carries out its functions in accordance with good clinical practices (e.g., ICH GCP Guidelines) and Health Canada regulations and in compliance with FDA 21 CFR parts 50 and 56, DHHS 45 CFR part 46, and the Tri-Council Policy Statement for Ethical Conduct of Research Involving Humans, as appropriate to the research.

Advarra IRB is registered with OHRP and FDA under IRB#00000971.

Please review the IRB Handbook located in the "Reference Materials" section of the Advarra CIRBI™ Platform (www.cirbi.net). A copy of the most recent IRB roster is also available.

Thank you for selecting Advarra IRB to provide oversight for your research project.

Sincerely,

Sara Harnish

Sara Harnish, JD
Executive Board Chair

372 Hollandview Trail, Suite 300
Aurora, ON L4G0A5 Canada
905-727-7989

# APPROVAL NOTICE/REB ATTESTATION

MOD00987375

| | |
|---|---|
| **DATE:** | 1 Jun 2021 |
| **TO:** | Chitra Karki, BAMS, MPH |
| **PROTOCOL:** | Takeda Pharmaceuticals, Inc - Pro00053638 / TAK-59, Burden of Illness in Crohn's Disease Patients with and without Perianal Fistulas (CPF and non-PAF): A study in EU4, Canada, Australia, & Japan (Pro00053638) |
| **APPROVAL DATE:** | 27 May 2021 |

## IRB APPROVED:

**Consent Form:**

- Informed Consent Form (Advarra IRB Approved Version 27 May 2021)

The IRB has reviewed and approved the above referenced documentation.

If there are any changes to the approved material, IRB approval will be needed prior to use. This includes changes in relative size and type of font in materials to be viewed by potential subjects.

The Consent Form referenced above is now available on your Advarra CIRBI Platform workspace. **The IRB determined new subjects be presented the above referenced Consent Form.**

**Compliance Statement/Attestation**

The IRB attests that the document(s) have been approved, as described above, and the membership of the IRB complies with the requirements defined in Health Canada regulations, 21 CFR parts 56 and 312.3 and 45 CFR 46. The IRB carries out its functions in accordance with good clinical practices (e.g., ICH GCP Guidelines) and Health Canada regulations and in compliance with FDA 21 CFR parts 50 and 56, DHHS 45 CFR part 46, and the Tri-Council Policy Statement for Ethical Conduct of Research Involving Humans, as appropriate to the research.

Advarra IRB is registered with OHRP and FDA under IRB#00000971.

Please review the IRB Handbook located in the "Reference Materials" section of the Advarra CIRBI™ Platform (www.cirbi.net). A copy of the most recent IRB roster is also available.

Thank you for continuing to use Advarra IRB to provide oversight for your research project.

Sincerely,

Sara Harnish, JD
Executive Board Chair

6100 Merriweather Dr., Suite 600
Columbia, MD 21044
410-884-2900

# EXEMPT DETERMINATION

**DATE:** 20 May 2021

**TO:** Chitra Karki, BAMS, MPH

**PROJECT:** Takeda Pharmaceuticals, Inc - Pro00053636 / TAK-59, Burden of Illness in Crohn's Disease Patients with and without Perianal Fistulas (CPF and non-PAF): A study in EU4, Canada, Australia, & Japan (Pro00053636)

---

## DOCUMENTATION REVIEWED:

**Protocol Version:**
- Protocol Version 4.0 (Dated 05 Apr 2021)

**Other Material:**
- Questionnaire, Observational Burden of Illness study in Perianal Fistula- and non-Perianal Fistula Crohn's Disease Patients (Not Dated)

Using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(2), the IRB determined that your research project is exempt from IRB oversight. All study related documents will be removed from our active files and archived.

Note: You will still be able to access this study via the Advarra CIRBI Platform under the "Archived" tab on your Dashboard for three years. After three years, the study will be removed from the system in accordance with IRB regulations.

The IRB granted this exemption with an understanding of the following:

1. The research project will only be conducted as submitted and presented to the IRB, without additional change in design or scope.

2. Should the nature of the research project change, or any aspect of the study change such that the nature of the study no longer meets the criteria found in 45 CFR 46.104(d)(2), you will resubmit revised materials for IRB review.

3. It is the responsibility of each investigator to ensure that the project meets the ethical standards of the institution. Specifically, the selection of subject is equitable, there are adequate provisions to maintain the confidentiality of any identifiable data collected, and when there are interactions with research subjects, they will be informed that the activity involves research, a description of the procedures, participation is voluntary, and the contact information for the researcher.

The IRB will evaluate the new information and make a determination at that time regarding the research project's status.

This project is not subject to requirements for continuing review.

If you have any questions or concerns, please use the Contact IRB activity on the Advarra CIRBI™ Platform.

Thank you for selecting Advarra IRB to review your research project.